Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 7/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17687636 | 1.00 | PANK3 (0.47) | PANK3GPR119RETAAK1PDE10A | |
| SCHEMBL26122583 | 0.89 | RET (0.47) | PANK3GPR119RETAAK1PDE10A | |
| SCHEMBL30546469 | 0.89 | RET (0.47) | PANK3GPR119RETAAK1PDE10A | |
| SCHEMBL24962330 | 0.86 | GPR119 (0.44) | GPR119RETAAK1PDE10ATACR3 | |
| SCHEMBL17687593 | 0.84 | GPR119 (0.52) | PANK3GPR119CHRM4 | |
| SCHEMBL29890792 | 0.84 | AAK1 (0.47) | PANK3GPR119RETAAK1PDE10A | |
| SCHEMBL26183968 | 0.84 | AAK1 (0.47) | PANK3GPR119RETAAK1PDE10A | |
| SCHEMBL595584 | 0.84 | AAK1 (0.47) | GPR119RETAAK1PDE10A | |
| SCHEMBL5542444 | 0.83 | GPR119 (0.51) | GPR119PDE10AAR | |
| SCHEMBL803847 | 0.80 | GPR119 (0.64) | GPR119AAK1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4051384-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | PANK3 162/4885GPR119 2891/4885RET 2188/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | PANK3 229/4885GPR119 3799/4885RET 2781/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | PANK3 165/4885GPR119 4379/4885RET 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.